MedTrace Logo

Vizol S DIGI EYE Efficacy and Safety Study in Patients With Dry Eye

NCT07050446 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 86

Last updated 2025-07-03

No results posted yet for this study

Summary

The clinical investigation was intended to investigate the efficacy, ocular tolerability and safety of Vizol S DIGI EYE, a new eye drops, solution developed by JADRAN - GALENSKI LABORATORIJ d.d., in patients with moderate to severe evaporative DED after a treatment for 28 days.

Conditions

  • Dry Eye Disease (DED)

Interventions

DRUG

Vizol S DIGI EYE eye drops

1 drop 4 times a day

DRUG

0,9% saline solution, eye drops

1 drop 4 times a day

Sponsors & Collaborators

  • Poseidon Clinical Research Balkans LLC

    collaborator UNKNOWN

  • Jadran Galenski laboratorij d.d.

    lead INDUSTRY

Principal Investigators

  • D. Veselinović, Prof. dr · Specialized clinic for eye disease - klinika Veselinović

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-03-20
Primary Completion
2024-08-23
Completion
2024-11-02

Countries

  • Serbia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07050446 on ClinicalTrials.gov